Cite
HARVARD Citation
Hvistendahl, M. et al. (2022). Bile acid–farnesoid X receptor–fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. JPEN, Journal of parenteral and enteral nutrition. 46 (4), pp. 923-935. [Online].